 |
|
|
|
3M Pharmaceuticals, a division of 3M Health Care, develops, manufactures and sells branded prescription drug products related to dermatology, women’s health, sexual health, cardiology and respiratory medicine. 3M Pharmaceuticals is one of the fastest growing businesses at 3M with a strong portfolio of innovative products and a robust pipeline of future drugs. Additional information is available at www.3M.com/pharma. Immune Response Modifiers (IRMs) are a new class of drugs developed by 3M Pharmaceuticals. IRMs work with the body’s own immune system to fight virus infected cells and tumour cells. Aldara (imiquimod) 5% cream is the first and only patient-applied topical treatment to combat the HPV virus that causes genital warts. 3M Canada recently submitted a supplemental new drug submission (sNDS) with Health Canada to market Aldara (imiquimod) 5% cream, for the treatment of actinic keratosis (AK). AK is a common, potentially serious skin condition caused by sun damage. 3M Company is a $16 billion (US) diversified technology company with leading positions in industrial, consumer and office, health care, safety, electronics, telecommunications and other markets. The company has operations in more than 60 countries and serves customers in nearly 200 countries. Established in 1951 as one of the first international subsidiaries of the global 3M Company, 3M Canada employs more than 1800 people across Canada and had annual sales exceeding $1 billion (CDN) in 2002. 3M Pharmaceuticals will continue to defend and grow its position in IRM science, establishing itself as a leader in dermatology.
Click here to close this window |
